Meeting Banner
Abstract #4768

Measuring the repeatability of an automated Whole-Body Diffusion-Weighted MRI tumour segmentation approach in metastatic prostate cancer

Antonio Candito1, Nina Tunariu1, Richard Holbrey1, Sebastian Schäfer2, Matthew R Orton1, David Collins1, Fabio Zugni3, Martin O Leach1, Matthias Baumhauer2, Matthew D Blackledge1, and Dow-Mu Koh1
1The Institute of Cancer Research, London, United Kingdom, 2Mint Medical, Heidelberg, Germany, 3IEO, European Institute of Oncology IRCCS, Milan, Italy

There is currently no accepted biomarker for assessing response to treatment in patients with bone disease from advanced prostate cancer (APC). Whole-Body Diffusion-Weighted-MRI (WBDWI) is emerging as a bone response biomarker in APC. However, automatic segmentation of disease from WBDWI is needed to quantify changes in WBDWI-derived biomarkers (global tumour apparent diffusion coefficient (gADC) and total tumour volume, tDV) for more reliable response assessment. We investigate the repeatability of WBMRI parameters using automatic disease delineation in APC patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here